Literature DB >> 24068787

Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study.

Hongliu Ding1, Kaltra Dhima, Kaitlin C Lockhart, Joseph J Locascio, Ashley N Hoesing, Karen Duong, Ana Trisini-Lipsanopoulos, Michael T Hayes, U Shivraj Sohur, Anne-Marie Wills, Brit Mollenhauer, Alice W Flaherty, Albert Y Hung, Nicte Mejia, Vikram Khurana, Stephen N Gomperts, Dennis J Selkoe, Michael A Schwarzschild, Michael G Schlossmacher, Bradley T Hyman, Lewis R Sudarsky, John H Growdon, Clemens R Scherzer.   

Abstract

OBJECTIVE: To conclusively test for a specific association between the biological marker 25-hydroxy-vitamin D3, a transcriptionally active hormone produced in human skin and liver, and the prevalence and severity of Parkinson disease (PD).
METHODS: We used liquid chromatography/tandem mass spectrometry to establish an association specifically between deficiency of 25-hydroxy-vitamin D3 and PD in a cross-sectional and longitudinal case-control study of 388 patients (mean Hoehn and Yahr stage of 2.1 ± 0.6) and 283 control subjects free of neurologic disease nested in the Harvard Biomarker Study.
RESULTS: Plasma levels of 25-hydroxy-vitamin D3 were associated with PD in both univariate and multivariate analyses with p values = 0.0034 and 0.047, respectively. Total 25-hydroxy-vitamin D levels, the traditional composite measure of endogenous and exogenous vitamin D, were deficient in 17.6% of patients with PD compared with 9.3% of controls. Low 25-hydroxy-vitamin D3 as well as total 25-hydroxy-vitamin D levels were correlated with higher total Unified Parkinson's Disease Rating Scale scores at baseline and during follow-up.
CONCLUSIONS: Our study reveals an association between 25-hydroxy-vitamin D3 and PD and suggests that thousands of patients with PD in North America alone may be vitamin D-deficient. This finding has immediate relevance for individual patients at risk of falls as well as public health, and warrants further investigation into the mechanism underlying this association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24068787      PMCID: PMC3888173          DOI: 10.1212/WNL.0b013e3182a95818

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Progression of parkinsonian signs in Parkinson disease.

Authors:  E D Louis; M X Tang; L Cote; B Alfaro; H Mejia; K Marder
Journal:  Arch Neurol       Date:  1999-03

Review 2.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

3.  RNA biomarkers of Parkinson's disease: developing tools for novel therapies.

Authors:  Gerrit Hennecke; Clemens R Scherzer
Journal:  Biomark Med       Date:  2008-02       Impact factor: 2.851

4.  Functional decline in Parkinson disease.

Authors:  J Jankovic; A S Kapadia
Journal:  Arch Neurol       Date:  2001-10

5.  High prevalence of hypovitaminosis D status in patients with early Parkinson disease.

Authors:  Marian L Evatt; Mahlon R DeLong; Meena Kumari; Peggy Auinger; Michael P McDermott; Vin Tangpricha
Journal:  Arch Neurol       Date:  2011-03

6.  Vitamin D receptor gene as a candidate gene for Parkinson disease.

Authors:  Megan W Butler; Amber Burt; Todd L Edwards; Stephan Zuchner; William K Scott; Eden R Martin; Jeffery M Vance; Liyong Wang
Journal:  Ann Hum Genet       Date:  2011-03       Impact factor: 1.670

7.  1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.

Authors:  Begoña Sanchez; Jose L Relova; Rosalia Gallego; Isabel Ben-Batalla; Roman Perez-Fernandez
Journal:  J Neurosci Res       Date:  2009-02-15       Impact factor: 4.164

8.  Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans.

Authors:  Joong-Seok Kim; Yeong-In Kim; Christopher Song; Injin Yoon; Jeong-Wook Park; Young-Bin Choi; Hee-Tae Kim; Kwang-Soo Lee
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

9.  Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease.

Authors:  Masahiko Suzuki; Masayuki Yoshioka; Masaya Hashimoto; Maiko Murakami; Miki Noya; Daisuke Takahashi; Mitsuyoshi Urashima
Journal:  Am J Clin Nutr       Date:  2013-03-13       Impact factor: 7.045

Review 10.  Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease.

Authors:  Darryl W Eyles; Thomas H J Burne; John J McGrath
Journal:  Front Neuroendocrinol       Date:  2012-07-11       Impact factor: 8.606

View more
  50 in total

1.  Parkinson disease: Low vitamin D and Parkinson disease--a causal conundrum.

Authors:  Marian L Evatt
Journal:  Nat Rev Neurol       Date:  2013-12-03       Impact factor: 42.937

2.  Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.

Authors:  Jose A Santiago; Judith A Potashkin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 3.  Vitamin D status and Parkinson's disease: a systematic review and meta-analysis.

Authors:  Zheng Lv; Huiping Qi; Le Wang; Xiaoxue Fan; Fei Han; Hong Wang; Sheng Bi
Journal:  Neurol Sci       Date:  2014-05-22       Impact factor: 3.307

Review 4.  Is there an association between diabetic neuropathy and low vitamin D levels?

Authors:  Zsuzsanna Putz; Tímea Martos; Nóra Németh; Anna Erzsébet Körei; Orsolya Erzsébet Vági; Miklós Soma Kempler; Péter Kempler
Journal:  Curr Diab Rep       Date:  2014-10       Impact factor: 4.810

5.  Serum Klotho, vitamin D, and homocysteine in combination predict the outcomes of Chinese patients with multiple system atrophy.

Authors:  Yue Guo; Xiao-Dong Zhuang; Wen-Biao Xian; Ling-Ling Wu; Ze-Na Huang; Xun Hu; Xiang-Song Zhang; Ling Chen; Xin-Xue Liao
Journal:  CNS Neurosci Ther       Date:  2017-06-19       Impact factor: 5.243

6.  Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study.

Authors:  Rachit Bakshi; Eric A Macklin; Albert Y Hung; Michael T Hayes; Bradley T Hyman; Anne-Marie Wills; Stephen N Gomperts; John H Growdon; Alberto Ascherio; Clemens R Scherzer; Michael A Schwarzschild
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

7.  Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Authors:  Michelle E Fullard; Sharon X Xie; Ken Marek; Matthew Stern; Danna Jennings; Andrew Siderowf; Allison W Willis; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2017-09-14       Impact factor: 10.338

8.  Seasonal temperature is associated with Parkinson's disease prescriptions: an ecological study.

Authors:  David Rowell; Son Nghiem; Sreeram Ramagopalan; Ute-Christiane Meier
Journal:  Int J Biometeorol       Date:  2017-08-30       Impact factor: 3.787

9.  Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.

Authors:  Srishti Shrestha; Pamela L Lutsey; Alvaro Alonso; Xuemei Huang; Thomas H Mosley; Honglei Chen
Journal:  Mov Disord       Date:  2016-04-19       Impact factor: 10.338

10.  The NINDS Parkinson's disease biomarkers program.

Authors:  Liana S Rosenthal; Daniel Drake; Roy N Alcalay; Debra Babcock; F DuBois Bowman; Alice Chen-Plotkin; Ted M Dawson; Richard B Dewey; Dwight C German; Xuemei Huang; Barry Landin; Matthew McAuliffe; Vladislav A Petyuk; Clemens R Scherzer; Coryse St Hillaire-Clarke; Beth-Anne Sieber; Margaret Sutherland; Chi Tarn; Andrew West; David Vaillancourt; Jing Zhang; Katrina Gwinn
Journal:  Mov Disord       Date:  2015-10-07       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.